| Severe Combined Immunodeficiency
Gamunex - C vs Octagam 5%
Side-by-side clinical, coverage, and cost comparison for severe combined immunodeficiency.Deep comparison between: Gamunex-C vs Octagam Immune Globulin (Human) with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOctagam Immune Globulin (Human) has a higher rate of injection site reactions vs Gamunex-C based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Octagam Immune Globulin (Human) but not Gamunex-C, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gamunex-C
Octagam Immune Globulin (Human)
At A Glance
IV infusion / SC injection
Every 3-4 weeks
Immune globulin
IV infusion
Every 3-4 weeks
Intravenous immunoglobulin (IVIG)
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Congenital agammaglobulinemia
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency, Congenital agammaglobulinemia IV: 300-600 mg/kg every 3-4 weeks; SC: initial weekly dose = prior monthly IGIV dose (g) x 1.37 divided by the number of weeks between IV doses, adjusted based on clinical response and IgG trough levels.
Immune thrombocytopenic purpura IV only: total dose of 2 g/kg given as 1 g/kg on two consecutive days or 0.4 g/kg on five consecutive days; do not administer subcutaneously.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating IV loading dose: 2 g/kg over 2-4 consecutive days; maintenance: 1 g/kg every 3 weeks (or 0.5 g/kg on two consecutive days every 3 weeks).
Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300-600 mg/kg IV every 3-4 weeks; adjust dose over time to achieve desired trough levels and clinical response.
Measles Exposure 400 mg/kg IV as soon as possible and within 6 days of exposure; increase to at least 530 mg/kg every 3-4 weeks if patient is at risk of future measles exposure.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity reaction
- Acute severe hypersensitivity reaction to human immunoglobulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity
- Acute hypersensitivity reaction to corn (product contains maltose derived from corn)
Adverse Reactions
Most common (>=5%) Headache, pyrexia, nausea, cough, rhinitis, pharyngitis, asthma, diarrhea, sinusitis, vomiting, ecchymosis, rash, arthralgia, chills, hypertension, asthenia, fatigue, local infusion site reactions (SC administration), upper respiratory tract infection, back pain, dyspepsia, abdominal pain.
Serious Exacerbation of autoimmune pure red cell aplasia, pulmonary embolism, hemolytic anemia.
Postmarketing Anaphylaxis, tachycardia, acute renal dysfunction/failure, acute respiratory distress syndrome, TRALI, pulmonary edema, bronchospasm, cardiac arrest, thromboembolism, vascular collapse, coma, seizures, aseptic meningitis, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, pancytopenia, leukopenia, hemolytic anemia, hepatic dysfunction.
Most common (>=5%) headache, nausea
Serious anaphylactic reactions, thromboembolic events, aseptic meningitis, hemolytic anemia
Postmarketing leukopenia, hemolytic anemia, anaphylactic shock, angioedema, cerebrovascular accident, myocardial infarction, pulmonary embolism, renal failure acute, transfusion-related acute lung injury
Pharmacology
GAMUNEX-C supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins; the precise mechanisms of action in ITP and CIDP have not been fully elucidated.
Intravenous immunoglobulin G preparation that supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacteria and their toxins; restores abnormally low IgG levels to the normal range in patients with primary humoral immunodeficiency.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gamunex-C
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (7/12) · Qty limit (0/12)
Octagam Immune Globulin (Human)
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (7/12) · Qty limit (0/12)
UnitedHealthcare
Gamunex-C
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Octagam Immune Globulin (Human)
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Gamunex-C
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Octagam Immune Globulin (Human)
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Gamunex-C.
No savings programs available for Octagam Immune Globulin (Human).
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Gamunex-CView full Gamunex-C profile
Octagam Immune Globulin (Human)View full Octagam Immune Globulin (Human) profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.